Results 31 to 40 of about 8,517,970 (127)

Real-world safety of aliskiren in primary hypertension: A cross-database study. [PDF]

PLoS ONE
Hypertension is one of the main causes of cardiovascular diseases worldwide, affecting over one billion people. Although aliskiren offers a valuable option for inhibiting the renin-angiotensin system, its safety profile in the real world remains ...
Meirong Shan, Qian Guo, Ruofei Li, Ni Li, Yanhua Fu, Huanyu Qi, Ge Zhang, Qian Wang, Xingli Xu, Jinchuan Lai   +9 more
doaj   +2 more sources

Original research a real-world study of adverse events of nafamostat mesylate and sodium citrate based on the world health organization-VigiAccess database [PDF]

Frontiers in Pharmacology
AimsWhile nafamostat mesylate (NM) and sodium citrate serve as commonly used extracorporeal anticoagulants in clinical practice, the characteristics and potential risks of their adverse events (AEs) need to be systematically evaluated.
Mengting Xu, Ziyi Wang, Binbin Yu
doaj   +2 more sources

Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports. [PDF]

Medicine (Baltimore)
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With its growing global use, continuous pharmacovigilance is essential to detect emerging patterns of adverse drug reactions (ADRs).
Alorfi NM, Alourfi MM, Aldabbagh A, Alghamdi WS, Al Ghamdi SS, Aldekhail NM, Alkhanani MF, Alansari AM, Alsolami FA, Ibrahim NA.   +9 more
europepmc   +2 more sources

Male sexual dysfunction associated with TNF-α inhibitors: an indication-stratified global pharmacovigilance analysis [PDF]

Frontiers in Pharmacology
BackgroundTumor necrosis factor-α (TNF-α) inhibitors are widely used for chronic inflammatory diseases, but their effects on male sexual health remain uncertain.
Yi Chu, Min Luo, Wenyu Li, Xuehong Wang, Yuqian Zhou   +4 more
doaj   +2 more sources

Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess. [PDF]

PLoS One
Introduction Antihistamines like azelastine and levocabastine are key in treating allergies, including allergic rhinitis, conjunctivitis, and urticaria.
Li Y, Zhu J, Guo Q, Liao J, Li L, Hu J, Zhang X.   +6 more
europepmc   +2 more sources

Muscle toxicity reports in FAERS: a disproportionality analysis with focus on rhabdomyolysis and cross-database assessment [PDF]

Frontiers in Pharmacology
ObjectiveMuscle toxicity can significantly impair quality of life and may be life-threatening in severe cases. Although statins are well known for their risk of muscle toxicity, a comprehensive evaluation of other implicated drugs remains limited.
Lei Zhang, Lei Zhang, Yuqi Wang, Fang Wang, Fang Wang, Kaiyun Ji, Kaiyun Ji, Lili Yang, Jia Li, Jia Li   +9 more
doaj   +2 more sources

Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models [PDF]

Exploratory Research in Clinical and Social Pharmacy
Background: Adverse drug reactions (ADRs) are critical in evaluating a medicine's safety profile during development and post-marketing surveillance. This study focuses on medications linked to major adverse drug reactions (ADRs) that were later taken off
Samadhan Ghubade, Sharvari Shukla
doaj   +2 more sources

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. [PDF]

Clin Pharmacol Ther
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +2 more sources

A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. [PDF]

Medicine (Baltimore)
The efficacy of anlotinib, gefitinib, afatinib, and osimertinib in the treatment of non-small cell lung cancer is well established, but there are gaps in the safety evidence. This study used real-world data from the World Health Organization-VigiAccess database to evaluate the post-marketing adverse drug ...
Fang C, Wu J, Hu C, Liu Q, Ma W, Zhang L, Hua P, Ding Y, Zhong Y.   +8 more
europepmc   +2 more sources

A severe case of rhabdomyolysis after Moderna mRNA anti‐COVID‐19 vaccine with a literature review

Clinical Case Reports, Volume 11, Issue 5, May 2023., 2023
The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is essential. As the symptoms of rhabdomyolysis are not specific, the threshold to actively search for this complication should be low. Abstract The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is ...
Maria Sheka, Yann Coattrenec, Kuntheavy Ing Lorenzini, Mathieu Nendaz   +3 more
wiley   +1 more source